\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ treatment\\/management\\:\\ no\\ known\\ effective\\ cure\\/treatment\\.\\ steroids\\ have\\ not\\ been\\ proven\\ to\\ change\\ course\\ of\\ disease\\ once\\ fibrosis\\ has\\ begun\\.\\ stopping\\ smoking\\ may\\ slow\\ progression\\.\\ neurofibromatosis\\ 1\\ has\\ soft\\ tissue\\ neoplastic\\ tendencies\\ that\\ should\\ be\\ monitored\\ periodically\\ for\\ interval\\ changes\\ if\\ there\\ is\\ suspicision\\ for\\ malignancy\\ or\\ if\\ the\\ patient\\ is\\ symptomatic\\.\ \(0\)\
\-\ cxr\\:\\ ill\\-defined\\ density\\ in\\ upper\\ lateral\\ peri\\-hilar\\ region\\ on\\ pa\\ view\\,\\ not\\ definitively\\ seen\\ on\\ lateral\\ projection\\,\\ but\\ possibly\\ more\\ anterior\\.\ \(0\)\
\-\ ct\\,\\ chest\\ w\\/contrast\\:\\ multiple\\ soft\\ tissue\\ attenuated\\ skin\\ nodules\\ noted\\ on\\ anterior\\ chest\\.\\ no\\ pulmonary\\ nodules\\ or\\ masses\\ seen\\.\\ \\ pulmonary\\ fibrosis\\ with\\ honey\\-combing\\ predominately\\ occurring\\ in\\ the\\ upper\\ lobes\\.\\ bullous\\ changes\\ are\\ seen\\ adjacent\\ to\\ mediastinum\\ near\\ azygoesophageal\\ recess\\.\\ pulmonary\\ scaring\\ and\\ honey\\-combing\\ extends\\ to\\ right\\ lower\\ lung\\.\ \(0\)\
\-\ pulmonary\\ manifestations\\ of\\ neurofibromatosis\\ 1\\.\\ however\\,\\ pulmonary\\ fibrosis\\ with\\ bullous\\ formation\\ from\\ smoking\\ related\\ pulmonary\\ diseases\\ can\\â\\€\\™t\\ be\\ ruled\\ out\\.\ \(0\)\
\-\ emphysema\ \(98\)\
\-\ idiopathic\\ pulmonary\\ fibrosis\\ \\(ipf\\)\ \(0\)\
\-\ autoimmune\\ disorders\\ \\(sarcoidosis\\,\\ ra\\)\ \(0\)\
\-\ collagen\\-vascular\\ diseases\\ with\\ fibrosising\\ aveolitits\ \(0\)\
\-\ 66\\ y\\.o\\.\\ female\\ with\\ nf1\\,\\ vomiting\\,\\ 25\\ pack\\ year\\ smoking\\ history\\,\\ no\\ history\\ of\\ copd\\.\\ \\ cxr\\ obtained\\ initially\\ and\\ chest\\ ct\\ later\\ obtained\\ for\\ further\\ evaluation\\ of\\ cxr\\ findings\\.\ \(0\)\
\-\ dx\\:\\ \\ pulmonary\\ fibrosis\\ with\\ bullous\\ formation\\ consistent\\ with\\ pulmonary\\ manifestations\\ of\\ neurofibromatosis\\ 1\\,\\ however\\,\\ smoking\\ related\\ pulmonary\\ diseases\\ can\\â\\€\\™t\\ be\\ ruled\\ out\\.\ \(0\)\
\-\ disease\\ discussion\\:\\ \\ neurofibromatosis\\ 1\\ \\(von\\ reckinghausen\\â\\€\\™s\\ disease\\,\\ or\\ nf1\\)\\,\\ is\\ a\\ autosomal\\ dominant\\ disorder\\ involving\\ chromosome\\ 17\\ of\\ probable\\ neural\\ crest\\ origin\\ affecting\\ all\\ 3\\ germinal\\ layers\\.\\ \\ considered\\ the\\ most\\ common\\ neurocutanous\\ disorder\\,\\ both\\ neuroectodermal\\ and\\ mesenchymal\\ derivatives\\.\\ \\ typically\\ nf1\\ is\\ recognized\\ on\\ clinical\\ exam\\ \\(85\\%\\ of\\ patients\\)\\ with\\ cutanous\\ neurofibromas\\.\\ \\ nf1\\ can\\ manifest\\ in\\ any\\ organ\\ in\\ the\\ body\\.\\ projection\\ of\\ neurofibromas\\ over\\ the\\ thorax\\ on\\ frontal\\ and\\ lateral\\ radiographs\\ may\\ be\\ misinterpreted\\ as\\ a\\ pulmonary\\ nodule\\ \\(as\\ demonstrated\\ on\\ above\\ cxr\\)\\,\\ so\\ it\\ is\\ important\\ to\\ use\\ ct\\ to\\ help\\ differentiate\\.\ \(0\)\
\-\ pulmonary\\ involvement\\ occurs\\ in\\ 10\\-20\\%\\ of\\ all\\ nf1\\ patients\\.\\ occurring\\ usually\\ not\\ until\\ adult\\ hood\\.\\ the\\ lung\\ parenchyma\\ can\\ progress\\ to\\ developing\\ interstitial\\ fibrosis\\ with\\ associated\\ severe\\ thin\\-walled\\ bullous\\ formations\\ reported\\ to\\ typically\\ occur\\ in\\ the\\ upper\\ lobes\\ and\\ apical\\ segments\\ of\\ the\\ lower\\ lobes\\ bilaterally\\ and\\ symmetrically\\.\\ honey\\-combing\\,\\ also\\ described\\ as\\ subpleural\\ small\\-blister\\-like\\ changes\\,\\ is\\ reportedly\\ seen\\ in\\ the\\ bibasilar\\ regions\\ of\\ the\\ lungs\\.\\ \\ these\\ findings\\ may\\ be\\ coincidental\\ with\\ other\\ lung\\ diseases\\,\\ however\\,\\ the\\ noted\\ mesenchymal\\ abnormalities\\ caused\\ by\\ nf1\\ may\\ affect\\ lung\\ parenchyma\\.\\ \\ the\\ pathology\\ of\\ the\\ lung\\ parenchyma\\ shows\\ alveolar\\ wall\\ thickening\\ progressing\\ to\\ fibrosis\\ and\\ lung\\ destruction\\.\\ pulmonary\\ function\\ tests\\ show\\ either\\ an\\ obstructive\\ or\\ a\\ restrictive\\ process\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pulmonary\\:\\ 0\\.3263663612198188\ \(0\)\
\-\ nf1\\:\\ 0\\.30001142420164006\ \(0\)\
\-\ fibrosis\\:\\ 0\\.24152236886943493\ \(0\)\
\-\ bullous\\:\\ 0\\.22728436219157475\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.16337207587382221\ \(0\)\
\-\ smoking\\:\\ 0\\.15257887103425274\ \(0\)\
\-\ diseases\\:\\ 0\\.15136266035799828\ \(0\)\
\-\ lung\\:\\ 0\\.15032554880097815\ \(0\)\
\-\ cxr\\:\\ 0\\.13179415836591293\ \(0\)\
\-\ the\\:\\ 0\\.1068367342600907\ \(0\)\
\-\ neurofibromas\\:\\ 0\\.10470302722809438\ \(0\)\
\-\ lobes\\:\\ 0\\.10309168523797071\ \(0\)\
\-\ parenchyma\\:\\ 0\\.10037246841854298\ \(0\)\
\-\ of\\:\\ 0\\.096720320793833\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.09646414961096567\ \(0\)\
\-\ can\\:\\ 0\\.08645359941115015\ \(0\)\
\-\ projection\\:\\ 0\\.08584027287987085\ \(0\)\
\-\ manifestations\\:\\ 0\\.08440936379754323\ \(0\)\
\-\ be\\:\\ 0\\.08353869635032098\ \(0\)\
\-\ occurring\\:\\ 0\\.08310754879708769\ \(0\)\
\-\ may\\:\\ 0\\.08290549495447974\ \(0\)\
\-\ ruled\\:\\ 0\\.08237930872096952\ \(0\)\
\-\ to\\:\\ 0\\.0823724650229708\ \(0\)\
\-\ seen\\:\\ 0\\.07756118857217548\ \(0\)\
\-\ changes\\:\\ 0\\.07467431107753719\ \(0\)\
\-\ on\\:\\ 0\\.07463428142962514\ \(0\)\
\-\ however\\:\\ 0\\.07313287723242681\ \(0\)\
\-\ with\\:\\ 0\\.0725835833718451\ \(0\)\
\-\ in\\:\\ 0\\.07172114943063611\ \(0\)\
\-\ disorder\\:\\ 0\\.06967815724256124\ \(0\)\
\-\ is\\:\\ 0\\.06767530929556516\ \(0\)\
\-\ upper\\:\\ 0\\.06602837321113722\ \(0\)\
\-\ tendencies\\:\\ 0\\.06586626957941247\ \(0\)\
\-\ suspicision\\:\\ 0\\.06586626957941247\ \(0\)\
\-\ fibrosising\\:\\ 0\\.06586626957941247\ \(0\)\
\-\ aveolitits\\:\\ 0\\.06586626957941247\ \(0\)\
\-\ reckinghausen\\:\\ 0\\.06586626957941247\ \(0\)\
\-\ neurocutanous\\:\\ 0\\.06586626957941247\ \(0\)\
\-\ cutanous\\:\\ 0\\.06586626957941247\ \(0\)\
\-\ nodules\\:\\ 0\\.0654504342640249\ \(0\)\
\-\ formation\\:\\ 0\\.0653045707225407\ \(0\)\
\-\ chest\\:\\ 0\\.065221054235784\ \(0\)\
\-\ not\\:\\ 0\\.06503789052709556\ \(0\)\
\-\ hood\\:\\ 0\\.06293873692870096\ \(0\)\
\-\ formations\\:\\ 0\\.06293873692870096\ \(0\)\
\-\ related\\:\\ 0\\.06259939743227558\ \(0\)\
\-\ lateral\\:\\ 0\\.061319949877570126\ \(0\)\
\-\ derivatives\\:\\ 0\\.060861619457221086\ \(0\)\
\-\ and\\:\\ 0\\.05957488304304241\ \(0\)\
\-\ misinterpreted\\:\\ 0\\.05925048197780621\ \(0\)\
\-\ obtained\\:\\ 0\\.058265776731219014\ \(0\)\
\-\ azygoesophageal\\:\\ 0\\.05793408680650958\ \(0\)\
\-\ coincidental\\:\\ 0\\.05793408680650958\ \(0\)\
\-\ typically\\:\\ 0\\.05782682597971433\ \(0\)\
\-\ or\\:\\ 0\\.057312277966171936\ \(0\)\
\-\ scaring\\:\\ 0\\.056821090547893686\ \(0\)\
\-\ ipf\\:\\ 0\\.056821090547893686\ \(0\)\
\-\ periodically\\:\\ 0\\.05500655415579806\ \(0\)\
\-\ stopping\\:\\ 0\\.05424583185561483\ \(0\)\
\-\ out\\:\\ 0\\.05414500731384065\ \(0\)\
\-\ restrictive\\:\\ 0\\.05355767482867797\ \(0\)\
\-\ chromosome\\:\\ 0\\.05235151361404719\ \(0\)\
\-\ disease\\:\\ 0\\.05186595928971711\ \(0\)\
\-\ begun\\:\\ 0\\.051816440425702305\ \(0\)\
\-\ germinal\\:\\ 0\\.051816440425702305\ \(0\)\
\-\ crest\\:\\ 0\\.05085231921283832\ \(0\)\
\-\ subpleural\\:\\ 0\\.05085231921283832\ \(0\)\
\-\ attenuated\\:\\ 0\\.05041459829368761\ \(0\)\
\-\ neuroectodermal\\:\\ 0\\.05041459829368761\ \(0\)\
\-\ symmetrically\\:\\ 0\\.05041459829368761\ \(0\)\
\-\ as\\:\\ 0\\.049638303962847394\ \(0\)\
\-\ manifest\\:\\ 0\\.04924118173342344\ \(0\)\
\-\ all\\:\\ 0\\.04903475120394761\ \(0\)\
\-\ recess\\:\\ 0\\.048553024706486585\ \(0\)\
\-\ reportedly\\:\\ 0\\.04792478656212681\ \(0\)\
\-\ if\\:\\ 0\\.04786082522152289\ \(0\)\
\-\ definitively\\:\\ 0\\.04763004425400857\ \(0\)\
\-\ progressing\\:\\ 0\\.04763004425400857\ \(0\)\
\-\ ct\\:\\ 0\\.04704032582506588\ \(0\)\
\-\ predominately\\:\\ 0\\.046558424520735234\ \(0\)\
\-\ bibasilar\\:\\ 0\\.046558424520735234\ \(0\)\
\-\ patients\\:\\ 0\\.04633938062115642\ \(0\)\
\-\ dx\\:\\ 0\\.04631364908271193\ \(0\)\
\-\ autoimmune\\:\\ 0\\.04607690053146608\ \(0\)\
\-\ anterior\\:\\ 0\\.04599233238116305\ \(0\)\
\-\ von\\:\\ 0\\.045625492055775076\ \(0\)\
\-\ layers\\:\\ 0\\.045409948171496226\ \(0\)\
\-\ recognized\\:\\ 0\\.045409948171496226\ \(0\)\
\-\ monitored\\:\\ 0\\.04423653161123206\ \(0\)\
\-\ copd\\:\\ 0\\.04388425765279941\ \(0\)\
\-\ soft\\:\\ 0\\.04385369207177597\ \(0\)\
\-\ noted\\:\\ 0\\.04367410349810004\ \(0\)\
\-\ differentiate\\:\\ 0\\.04338611643200042\ \(0\)\
\-\ alveolar\\:\\ 0\\.04322742468329145\ \(0\)\
\-\ tissue\\:\\ 0\\.043211078018855716\ \(0\)\
\-\ pack\\:\\ 0\\.04277126139418352\ \(0\)\
\-\ probable\\:\\ 0\\.042625394131817186\ \(0\)\
\-\ affect\\:\\ 0\\.042625394131817186\ \(0\)\
\-\ autosomal\\:\\ 0\\.04248241552078471\ \(0\)\
\-\ organ\\:\\ 0\\.04234221336966442\ \(0\)\
\-\ apical\\:\\ 0\\.04234221336966442\ \(0\)\
\-\ lower\\:\\ 0\\.04209275035079469\ \(0\)\
\-\ effective\\:\\ 0\\.04206972126070379\ \(0\)\
\-\ progress\\:\\ 0\\.04193723710488033\ \(0\)\
\-\ segments\\:\\ 0\\.041807140181319535\ \(0\)\
\-\ thorax\\:\\ 0\\.04167934597948538\ \(0\)\
\-\ proven\\:\\ 0\\.041553774398543845\ \(0\)\
\-\ affecting\\:\\ 0\\.04143034944580683\ \(0\)\
\-\ ra\\:\\ 0\\.040731075890249546\ \(0\)\
\-\ findings\\:\\ 0\\.04065443489643247\ \(0\)\
\-\ emphysema\\:\\ 0\\.04040529804930484\ \(0\)\
\-\ no\\:\\ 0\\.040180198201465234\ \(0\)\
\-\ slow\\:\\ 0\\.03969786148110567\ \(0\)\
\-\ developing\\:\\ 0\\.03941468071895291\ \(0\)\
\-\ tests\\:\\ 0\\.03941468071895291\ \(0\)\
\-\ once\\:\\ 0\\.038709713011749816\ \(0\)\
\-\ possibly\\:\\ 0\\.038709713011749816\ \(0\)\
\-\ 66\\:\\ 0\\.03862624174783234\ \(0\)\
\-\ dominant\\:\\ 0\\.03854372446210382\ \(0\)\
\-\ obstructive\\:\\ 0\\.03830168446033702\ \(0\)\
\-\ neural\\:\\ 0\\.038144717758563186\ \(0\)\
\-\ neoplastic\\:\\ 0\\.03806749580414109\ \(0\)\
\-\ 85\\:\\ 0\\.03799109102859063\ \(0\)\
\-\ adult\\:\\ 0\\.03799109102859063\ \(0\)\
\-\ help\\:\\ 0\\.03784066508949957\ \(0\)\
\-\ progression\\:\\ 0\\.03776661127199213\ \(0\)\
\-\ has\\:\\ 0\\.03762563752243298\ \(0\)\
\-\ destruction\\:\\ 0\\.037548900790874015\ \(0\)\
\-\ for\\:\\ 0\\.03744998720137974\ \(0\)\
\-\ interstitial\\:\\ 0\\.03733756324747304\ \(0\)\
\-\ interval\\:\\ 0\\.037268470051193145\ \(0\)\
\-\ mediastinum\\:\\ 0\\.03686724550585572\ \(0\)\
\-\ disorders\\:\\ 0\\.03636476913997744\ \(0\)\
\-\ steroids\\:\\ 0\\.03618500423829338\ \(0\)\
\-\ discussion\\:\\ 0\\.036067600287083314\ \(0\)\
\-\ origin\\:\\ 0\\.03545393365909753\ \(0\)\
\-\ regions\\:\\ 0\\.0353477525702971\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.03488836334447037\ \(0\)\
\-\ important\\:\\ 0\\.03488836334447037\ \(0\)\
\-\ idiopathic\\:\\ 0\\.03483907862128062\ \(0\)\
\-\ so\\:\\ 0\\.03464523653846991\ \(0\)\
\-\ until\\:\\ 0\\.034272499125868716\ \(0\)\
\-\ either\\:\\ 0\\.034048946162662505\ \(0\)\
\-\ extends\\:\\ 0\\.03391806311204855\ \(0\)\
\-\ 17\\:\\ 0\\.03362159162564095\ \(0\)\
\-\ near\\:\\ 0\\.033539074339912434\ \(0\)\
\-\ described\\:\\ 0\\.03341704015746049\ \(0\)\
\-\ function\\:\\ 0\\.033336815066396346\ \(0\)\
\-\ caused\\:\\ 0\\.033024542229185\ \(0\)\
\-\ nodule\\:\\ 0\\.032508595367025064\ \(0\)\
\-\ occurs\\:\\ 0\\.03247311527640194\ \(0\)\
\-\ pathology\\:\\ 0\\.03233291312528165\ \(0\)\
\-\ initially\\:\\ 0\\.03229828387946239\ \(0\)\
\-\ considered\\:\\ 0\\.03209392541014356\ \(0\)\
\-\ symptomatic\\:\\ 0\\.03167004573510261\ \(0\)\
\-\ pa\\:\\ 0\\.03160698695949381\ \(0\)\
\-\ use\\:\\ 0\\.031513419551824025\ \(0\)\
\-\ history\\:\\ 0\\.0314712975169486\ \(0\)\
\-\ change\\:\\ 0\\.031210005837089386\ \(0\)\
\-\ process\\:\\ 0\\.030890347907801097\ \(0\)\
\-\ malignancy\\:\\ 0\\.03083371872407279\ \(0\)\
\-\ skin\\:\\ 0\\.030638942799555504\ \(0\)\
\-\ vomiting\\:\\ 0\\.030476074602571696\ \(0\)\
\-\ course\\:\\ 0\\.030422591514223225\ \(0\)\
\-\ lungs\\:\\ 0\\.03039599780492207\ \(0\)\
\-\ occur\\:\\ 0\\.03029059178819717\ \(0\)\
\-\ view\\:\\ 0\\.03016096202415339\ \(0\)\
\-\ abnormalities\\:\\ 0\\.029834428499089235\ \(0\)\
\-\ involvement\\:\\ 0\\.02980991172200918\ \(0\)\
\-\ above\\:\\ 0\\.029712668717926168\ \(0\)\
\-\ reported\\:\\ 0\\.02966453398023103\ \(0\)\
\-\ later\\:\\ 0\\.029475141248300717\ \(0\)\
\-\ 25\\:\\ 0\\.02917759552958128\ \(0\)\
\-\ involving\\:\\ 0\\.028848850557469313\ \(0\)\
\-\ masses\\:\\ 0\\.02803901843317857\ \(0\)\
\-\ thickening\\:\\ 0\\.028019892106993616\ \(0\)\
\-\ available\\:\\ 0\\.02794388946928685\ \(0\)\
\-\ bilaterally\\:\\ 0\\.027468465154210562\ \(0\)\
\-\ density\\:\\ 0\\.027310927619222\ \(0\)\
\-\ body\\:\\ 0\\.02710608596821841\ \(0\)\
\-\ should\\:\\ 0\\.026874225277192628\ \(0\)\
\-\ further\\:\\ 0\\.02682549494207357\ \(0\)\
\-\ radiographs\\:\\ 0\\.026713053765567017\ \(0\)\
\-\ adjacent\\:\\ 0\\.026697132736155208\ \(0\)\
\-\ known\\:\\ 0\\.02666539561291123\ \(0\)\
\-\ any\\:\\ 0\\.026618049974978922\ \(0\)\
\-\ frontal\\:\\ 0\\.026508769429632643\ \(0\)\
\-\ show\\:\\ 0\\.026146173548194488\ \(0\)\
\-\ clinical\\:\\ 0\\.026102103112818985\ \(0\)\
\-\ severe\\:\\ 0\\.026072871559074538\ \(0\)\
\-\ usually\\:\\ 0\\.02592846306707637\ \(0\)\
\-\ demonstrated\\:\\ 0\\.0253121492588913\ \(0\)\
\-\ evaluation\\:\\ 0\\.02511787250018794\ \(0\)\
\-\ wall\\:\\ 0\\.025054258133496352\ \(0\)\
\-\ region\\:\\ 0\\.024635936294087144\ \(0\)\
\-\ shows\\:\\ 0\\.024172945407389897\ \(0\)\
\-\ been\\:\\ 0\\.023995754087594665\ \(0\)\
\-\ common\\:\\ 0\\.023357494867493445\ \(0\)\
\-\ these\\:\\ 0\\.023258041726024952\ \(0\)\
\-\ both\\:\\ 0\\.02296764666470814\ \(0\)\
\-\ over\\:\\ 0\\.022901535951169893\ \(0\)\
\-\ more\\:\\ 0\\.022615824518416223\ \(0\)\
\-\ consistent\\:\\ 0\\.02233229620595351\ \(0\)\
\-\ associated\\:\\ 0\\.02170840364337563\ \(0\)\
\-\ most\\:\\ 0\\.021434730994204277\ \(0\)\
\-\ other\\:\\ 0\\.021388839840266842\ \(0\)\
\-\ it\\:\\ 0\\.021082822420448843\ \(0\)\
\-\ exam\\:\\ 0\\.020733332952568507\ \(0\)\
\-\ have\\:\\ 0\\.020574943930591207\ \(0\)\
\-\ but\\:\\ 0\\.020366816362352966\ \(0\)\
\-\ multiple\\:\\ 0\\.020145240984405136\ \(0\)\
\-\ female\\:\\ 0\\.01987441297789622\ \(0\)\
\-\ also\\:\\ 0\\.01937297562195089\ \(0\)\
\-\ that\\:\\ 0\\.017873420797234512\ \(0\)\
\-\ by\\:\\ 0\\.017490200442654258\ \(0\)\
\-\ there\\:\\ 0\\.01638800285991886\ \(0\)\
\-\ from\\:\\ 0\\.016357553963288803\ \(0\)\
\-\ an\\:\\ 0\\.015749600809023823\ \(0\)\
\-\ are\\:\\ 0\\.01562842489509148\ \(0\)\
\-\ right\\:\\ 0\\.013655047482867645\ \(0\)\
\-\ patient\\:\\ 0\\.013395919094777695\ \(0\)\
\-\ year\\:\\ 0\\.012692885702983082\ \(0\)\
